Compare EDRY & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDRY | CHRS |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.6M | 159.1M |
| IPO Year | 2018 | 2014 |
| Metric | EDRY | CHRS |
|---|---|---|
| Price | $33.32 | $0.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $55.67 | $7.25 |
| AVG Volume (30 Days) | 79.7K | ★ 2.6M |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.38 | $34.48 |
| Revenue Next Year | $14.31 | $54.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.30 | $0.37 |
| 52 Week High | $73.07 | $2.62 |
| Indicator | EDRY | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 35.35 | 23.34 |
| Support Level | $19.19 | N/A |
| Resistance Level | $46.44 | $1.53 |
| Average True Range (ATR) | 3.88 | 0.07 |
| MACD | -0.09 | -0.03 |
| Stochastic Oscillator | 10.64 | 1.64 |
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.